๐ฌ NT-I7 + BCMA CAR-T(Carvykti) ๋ณ์ฉ ์ฐ๊ตฌ์์ฃผ๋์์ NIT-128, ์ฒซ ํ์ ํฌ์ฌ ๊ฐ์, WashU์ Michael SladeยทJohn F. DiPersio ๋ฐ์ฌ ์ฃผ๋. ๋ค๋ฐ์ฑ๊ณจ์์ข
๋์ BCMA CAR-T ์น๋ฃ ํ NT-I7 ๋ณ์ฉ ํ๊ฐ ๐ bit.ly/4hSkqtt #NTI7 #CART
8
๐ฌ WashU has dosed the first patient in NIT-128, evaluating NT-I7 in combination with BCMA CAR-T therapy in relapsed/refractory multiple myeloma. Led by Dr. Michael Slade & Dr. John F. DiPersio ๐ bit.ly/4cwWXL1 NTI7 #CART
10
๐ค ๋ค์ค์ด๋ฎจํ
์ด Tolerance Bio์ ๋ฏธ์ฃผยท์ ๋ฝ ๋ด ํ์ ๊ธฐ๋ฅ๋ถ์ ๊ด๋ จ ์ ์์ฆ์ NT-I7 ๊ธฐ์ ์ด์ ๊ณ์ฝ์ ์ฒด๊ฒฐํ์ต๋๋ค. ์๋์ฌ ์ง๋ถ๊ณผ ์ต๋ 2์ต6,000๋ง ๋ฌ๋ฌ ๊ท๋ชจ์ ๋ง์ผ์คํค, ๋จ๊ณ๋ณ ๋ก์ดํฐ๋ฅผ ์์ทจํ ์์ ์
๋๋ค. ๐ bit.ly/4zGa2vo #๋ค์ค์ด๋ฎจํ
#NTI7 #๊ธฐ์ ์ด์ #๋ฉด์ญ์งํ
16
๐ค NeoImmuneTech signs its first post-listing licensing deal with Tolerance Bio. NT-I7 will be developed for thymic insufficiency-related indications in the Americas & Europe. Includes equity, up to $260M in milestones & tiered royalties. ๐ bit.ly/4gFUvnD #NTI7 #Biotech
23
๐ ๋ค์ค์ด๋ฎจํ
, NT-I7๊ณผ oncolytic virus ๋ณ์ฉ ์ฐ๊ตฌ๊ฐ ๊ตญ์ ํ์ ์ง Nature communications (IF: 15.7)์ ๊ฒ์ฌ. NT-I7์ ํ์ฉํ โExpand & Pullโ ์ ๋ต์ผ๋ก ์ ์ T ์ธํฌ๋ฅผ ์ฆํญ์ํค๊ณ ์ข
์์ผ๋ก ์ ๋ํ๋ ์๋ก์ด ๋จ๊ณ์ ๋ฉด์ญ ์น๋ฃ ์ ๊ทผ๋ฒ ์ ์
๐bit.ly/3MU3FAS #๋ค์ค์ด๋ฎจํ
#NTI7
46
๐ New glioblastoma immunotherapy research featuring NeoImmuneTechโs NT-I7 is now published in Nature Communications(IF: 15.7). A novel โExpand & Pullโ strategy for next-generation T cell therapy.
๐ bit.ly/46eQYXX #NeoImmuneTech #Immunotherapy #NTI7
1
28
๐ ๋ค์ค์ด๋ฎจํ
, FDA ์น์ธ ๊ฒธ์์ ํ๊ตฌ์งํ ์น๋ฃ์ Endari ๋ฐ ๊ด๋ จ ์ ๋ค๋ฆญ์ ๋ถ๋ฏธ ๋
์ ํ๋งค ๋ฐ ๊ฐ๋ฐ ๊ถ๋ฆฌ ์ต์ข
๊ณ์ฝ ์ฒด๊ฒฐ ์๋ฃ. ์ด๋ฅผ ํตํ ๋ถ๋ฏธ ์์ฅ์์์ ์์
ํ ์ญ๋ ์ถ์ ๊ณผ ํฅํ ์์
ํ๋ฅผ ์ํ ์ค์ํ ๋ฐํ ๋ง๋ จ ๐ bit.ly/4jg1WBG #๋ค์ค์ด๋ฎจํ
#Endari #ํฌ๊ท์งํ #NTI7
1
117
๐ NeoImmuneTech finalizes exclusive North American rights to FDA-approved Endariยฎ โ securing commercial revenue potential and strengthening the path toward NT-I7 commercialization. ๐ bit.ly/4pSY0t6 #NeoImmuneTech #Endari #SCD #NTI7
37
๐ฌ ASH 2025
NT-I7 + CD19 CAR-T ๋ณ์ฉ ์์, ๊ตฌ๋ ๋ฐํ โ ์์ ์ฑ ๋ฐ ๋ด์ฝ์ฑ ์ฐ์, ํ์ฌ 10์ผยท31์ผ ํฌ์ฌ ํ๊ฐ ์งํ ์ค
NT-I7 + CAR-T + ๋ฑ์ฌ๋ฉํ์, ์ผ์ค ๋ณ์ฉ ๋น์์, ํฌ์คํฐ ๋ฐํ โ 100์ผ ์ด์ ์์ ๊ดํด ์ ์ง
๐ bit.ly/48SMCGo #NTI7 #CART #ASH2025
62
๐ฌ ASH 2025: NT-I7 enhanced CAR-T expansion & persistence; preclinical data also showed improved long-term durability with dexamethasone.
๐ bit.ly/3MHgT3B #NTI7 #CART #ASH2025
62
๐ฌ NT-I7 + BCMA CAR-T(CARVYKTIยฎ) ๋ณ์ฉ ์ฐ๊ตฌ์์ฃผ๋์์ NIT-128, FDA IND ์น์ธ
WashU์ Michael SladeยทJohn DiPersio ๋ฐ์ฌ ์ฃผ๋. CAR-T ์น๋ฃ ํ 14์ผ, 35์ผ 2ํ ํฌ์ฌ๋ก ๋ฉด์ญ ํ๋ณต๊ณผ CAR-T ์ง์์ฑ ํฅ์ ํ๊ฐ
๐ bit.ly/4i6FKcE #NTI7 #CART
1
137
๐ฌFDA clears IND for NIT-128, an IIT led by WashUโs Dr. Michael Slade and Dr. John DiPersio testing NT-I7+CARVYKTIยฎ in multiple myeloma.
Two postโCAR-T doses(Day 14 & 35)will assess whether NT-I7 enhances immune recovery and CAR-T persistence.๐bit.ly/4a2jK0w #NTI7 #CART
1
127
๐ ๋ค์ค์ด๋ฎจํ
, NT-I7 + BCMA CAR-T ๋ณ์ฉ ์์ ็พ FDA IND ์ ์ถ
WashU Medicine์ด ๋ค๋ฐ์ฑ๊ณจ์์ข
(MM) ํ์ ๋์ ์ฐ๊ตฌ์์ฃผ๋์์ IND๋ฅผ FDA์ ์ ์ถ
๋ง์ดํด ์ฌ๋ ์ด๋ ์กฐ๊ต์ ์ฃผ๋, ์กด ๋ํผ์์ค ๊ต์ ํ๋ ฅ
NT-I7์ CAR-T ๋ณ์ฉ ์ ๋ต BCMA๋ก ํ์ฅ
๐ bit.ly/4388ED4 #NeoImmuneTech #NTI7 #CART
29
๐ NeoImmuneTech Announces IND for NT-I7 + BCMA CAR-T Trial WashU Med filed IND for Ph1 of NT-I7+BCMA CAR-T in multiple myeloma, led by Dr. Slade in collab with Dr. DiPersio, expanding NT-I7's CAR-T strategy ๐ท bit.ly/3Jw6kyY #NeoImmuneTech #NTI7 #CART
23
๐ฌ ็พ FDA, CAR-T ๋ณ์ฉ NT-I7 ๋ฐ๋ณตํฌ์ฌ ์ฐ๊ตฌ์ ์ฃผ๋ ์์ ์น์ธ
John DiPersioยทZachary D. Crees ๋ฐ์ฌ ์ฃผ๋, 10์ผ์ฐจยท31์ผ์ฐจ ํฌ์ฌ ์ ๋ต์ผ๋ก CAR-T ์ง์์ฑยทํจ๊ณผ ํฅ์ ๋ชฉํ
๐ bit.ly/4fy1DAf #NTI7 #CART #์์์ํ #๋ฉด์ญํญ์์
36
๐ฌ FDA has cleared an IIT led by Drs. John DiPersio & Zachary D. Crees testing repeat dosing of NT-I7 (efineptakin alfa) post CAR-T in r/r LBCL.
Two-dose strategy on Days 10 & 31 aims to boost CAR-T persistence & durability.
๐ bit.ly/46Slwjq#NTI7 #CART #Immunotherapy
29
NT-I7ยทCAR-T ๋ณ์ฉ ํ์ ์์, ็พ FDA์ IND ์ ์ถ!
์์ฑํด๋ John DiPersio ๋ฐ์ฌ ์ฃผ๋ ์ฐ๊ตฌ์ ์์์์#LBCL ํ์ ๋์์ผ๋ก NT-I7 10์ผยท31์ผ ๋ฐ๋ณต ํฌ์ฌ ์ ๋ต์ ํตํด ์น๋ฃ ๋ฐ์์ ๊ทน๋ํ ํ๊ณ ์ ํฉ๋๋ค.
๐ bit.ly/46Hfe5Y #NeoImmuneTech #Immunotherapy #CART
30
IND submitted to the FDA for a follow-up trial of #NTI7 + CAR-T!
Led by Dr. John DiPersio, this IIT explores a repeated dosing strategy (Day 10 & 31) in #LBCL patients.
๐bit.ly/3IpyJGa #NeoImmuneTech #Immunotherapy #CART
25
๋ค์ค์ด๋ฎจํ
, NT-I7+CAR-T ๋ณ์ฉ ์์ ์ต์ข
๊ฒฐ๊ณผ ๋ฐํ
๐ฅ๊ณ ์ฉ๋๊ตฐ ๋ฐ์๋ฅ 100% ๋ฐ 6๊ฐ์ ์ด์ ์ง์ 88%
๐ก๏ธ NT-I7 ํฌ์ฌ ์ดํ CRSยทICANS ์ด์๋ฐ์ โ0๊ฑดโ
๐งฌRP2D 720 ฮผg/kg
BIO 2025์์ ๊ธ๋ก๋ฒ ์ ์ฝ์ฌ์ ํ์ ๋
ผ์๋ฅผ ์ด์ด ๋๊ฐ ์์ ์
๋๋ค
๐ bit.ly/43BMnxZ
#๋ค์ค์ด๋ฎจํ
#CAR_T #NTI7 #๋ฉด์ญํญ์
84
Final results from NeoImmuneTechโs Ph1b trial of NT-I7 + CAR-T! 100% ORR in high-dose cohort and 88% maintained response >6mo๐ก๏ธ No CRS or ICANS after NT-I7 ๐งฌ RP2D: 720 ฮผg/kg ๐ค Partner talks ongoing โ meet us at #BIO2025!
๐bit.ly/4mnfYCA
#CAR_T #NTI7 #Immunotherapy
2
53






